Minimal flow sevoflurane and isoflurane anaesthesia and impact on renal function

European Journal of Anaesthesiology

Volumn 18, Issue 1, 2001, Pages 43-50

  Goeters, C ^a   Reinhardt, C ^a   Gronau, E ^a   Wusten R ^a   Prien, T ^a   Baum, J ^b   Vrana, S ^c   Van Aken, H ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Abteilung fur Anästhesie und Intensivmedizin des St Elisabeth Stiftes Damme   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

ANAESTHESIA, GENERAL; Closed circuit; GASES, carbon dioxide; Inhalation; INTRAOPERATIVE COMPLICATIONS, Biodegradation; POISONING, gas poisoning, compound A

Indexed keywords

DRUG METABOLITE; ISOFLURANE; SEVOFLURANE;

ADULT; ARTICLE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; GAS FLOW; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY;

ADULT; ANESTHESIA, INHALATION; ANESTHETICS, INHALATION; FEMALE; HUMANS; ISOFLURANE; KIDNEY; KIDNEY FUNCTION TESTS; MALE; METHYL ETHERS;

EID: 0035130469     PISSN: 02650215     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2346.2001.00773.x     Document Type: Article

References (21)

1. Carbon monoxide production from degradation of desflurane, enflurane, isoflurane, halothane and sevoflurane by soda lime and baralyme
2. Sevoflurane degradation to compound A in anaesthesia breathing systems
3. Inhalation toxicology study of haloalkene degradant of sevoflurane, Compound A (PIFE) in Sprague-Dawley rats
4. Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity
5. Effects of low-flow sevoflurane on renal function. Comparison with high-flow sevoflurane and low-flow isoflurane anesthesia
6. Effects of sevoflurane and isoflurane on renal function and on possible markers of nephrotoxicity
7. Nephrotoxicity of sevoflurane versus desflurane anesthesia in volunteers
8. Dose-related biochemical markers of renal injury after sevoflurane versus desflurane anesthesia in volunteers
9. Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers
10. Cysteine conjugate β-lyase-dependent metabolism of compound A (2-[fluoromethoxy]-1,1,1,3,3,3-pentafluoro-1-propene) in human subjects anesthetized with sevoflurane and in rats given compound A
11. Cysteine conjugate β-lyase-dependent biotransformation of cysteine S-conjugates of the sevoflurane degradation product compound A in human, nonhuman primate, and rat kidney cytosol and mitochondria
12. Atemgasklimatisierung und Klimaprofil des Narkosegerätes Dräger Cicero
13. Analysis of sevoflurane degradation products in vapor phase samples
14. In vitro analysis of compound A formation by sevoflurane in a computer controlled closed circuit Physioflex anesthesia apparatus
15. Compound A does not accumulate during closed circuit sevoflurane anaesthesia with the Physioflex
16. Comparison of compound A with sevoflurane anaesthesia using a closed system with a Physioflex anaesthesia machine vs. a low-flow system with a conventional anaesthesia machine
17. Urineiweiβ-Differenzierung. Ein neues Konzept zur nichtinvasiven Diagnostik von Nierenerkrankungen
18. Strategies and criteria for developing new urinalysis tests
19. The renal safety of sevoflurane
20. Absorbents differ enormously in their capacity to produce compound A and carbon monoxide